Ensayos clínicos

8.676 ensayos encontrados

Activo, no reclutaFase 3ClinicalTrials.gov

CYCLONE 3: Estudio de fase 3, aleatorizado, doble ciego, controlado con placebo de abemaciclib en combinación con abiraterona más prednisona en hombres con cáncer de próstata metastásico con sensibilidad hormonal de alto riesgo

IntervencionalInicio: 14 de abr de 2022ID: NCT05288166

CompletadoFase 2ClinicalTrials.gov

A Phase II, Open-Label, Randomized, Multicenter Trial of Pazopanib (GW786034) in Combination With Lapatinib (GW572016) Compared to Pazopanib Monotherapy and Lapatinib Monotherapy in Subjects With FIGO Stage IVB or Recurrent or Persistent Cervical Cancer With Zero or One Prior Chemotherapy Regimen

IntervencionalInicio: 1 de nov de 2006ID: NCT00430781

CompletadoFase 2ClinicalTrials.gov

The TEAM Trial (Tasigna Efficacy in Advanced Melanoma): A Phase II, Open Label, Multi-center, Single-arm Study to Assess the Efficacy of Tasigna ® in the Treatment of Patients With Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

IntervencionalInicio: 1 de jun de 2010ID: NCT01028222

CompletadoClinicalTrials.gov

Evaluación de la relación entre la inasistencia a turnos y la adherencia a las indicaciones médicas, en pacientes adultos con diabetes mellitus tipo 2, durante la pandemia de COVID-19: estudio transversal.

ObservacionalInicio: 1 de jul de 2020ID: NCT06501456

CompletadoFase 3ClinicalTrials.gov

A Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD) -Study 1

IntervencionalInicio: 1 de oct de 2013ID: NCT01957163

ReclutandoFase 3ClinicalTrials.gov

Estudio de fase 3, aleatorizado, abierto, de palazestrant (OP-1250) en monoterapia versus el estándar de atención para el tratamiento del cáncer de mama avanzado o metastásico ER+, HER2- tras tratamiento con terapia endocrina e inhibidores de CDK 4/6 (OPERA-01)

IntervencionalInicio: 16 de nov de 2023ID: NCT06016738

ReclutandoFase 2ClinicalTrials.gov

Estudio de Fase IIb, Aleatorizado, Doble Ciego, Controlado con Placebo, Paralelo, de Dosis Múltiples, Multinacional, para Evaluar la Eficacia, Seguridad y FC de AZD0292 en Participantes de 12 Años de Edad o Mayores con Bronquiectasias y Colonización Crónica por Pseudomonas Aeruginosa

IntervencionalInicio: 6 de nov de 2025ID: NCT07088926

TerminadoFase 3ClinicalTrials.gov

A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Hospitalized Patients With Influenza A Infection

IntervencionalInicio: 3 de ene de 2018ID: NCT03376321

CompletadoFase 3ClinicalTrials.gov

A Phase III, Open-Label, Randomized Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Patients With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer Who Have Not Progressed After Concurrent Platinum-Based Chemoradiation

IntervencionalInicio: 24 de ago de 2020ID: NCT04513925

CompletadoFase 2ClinicalTrials.gov

A 24-week, Double-Blind, Randomized, Parallel Group, Placebo-Controlled, Phase 2 Study of Different Doses of VX-509 in Adult Subjects With Active Rheumatoid Arthritis on Stable Methotrexate Therapy With 104-Week Open Label Extension

IntervencionalInicio: 1 de abr de 2012ID: NCT01590459

CompletadoFase 3ClinicalTrials.gov

Phase 3 Trial to Investigate the Efficacy, Safety, and Tolerability of Blinatumomab as Consolidation Therapy Versus Conventional Consolidation Chemotherapy in Pediatric Subjects With HR First Relapse B-precursor ALL

IntervencionalInicio: 10 de nov de 2015ID: NCT02393859

CompletadoFase 3ClinicalTrials.gov

EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF TOFACITINIB FOR TREATMENT OF SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (SJIA) WITH ACTIVE SYSTEMIC FEATURES IN CHILDREN AND ADOLESCENT SUBJECTS

IntervencionalInicio: 10 de may de 2018ID: NCT03000439

TerminadoFase 3ClinicalTrials.gov

A Phase 3, Randomized, Multicenter, Placebo-controlled, Double-blind Clinical Study of the Safety and Efficacy of Carrimycin for Treatment of Severe COVID-19 in Hospitalized Patients

IntervencionalInicio: 30 de mar de 2021ID: NCT04672564

CompletadoFase 3ClinicalTrials.gov

Safety and Efficacy of Exenatide Once Weekly Injection Versus Metformin, Dipeptidyl Peptidase-4 Inhibitor, or Thiazolidinedione as Monotherapy in Drug-Naive Patients With Type 2 Diabetes

IntervencionalInicio: 1 de nov de 2008ID: NCT00676338

CompletadoFase 3ClinicalTrials.gov

A Randomized Placebo Controlled Study Of OSI-774 (TARCEVA) Plus Gemcitabine In Patients With Locally Advanced, Unresectable Or Metastatic Pancreatic Cancer

IntervencionalInicio: 29 de oct de 2001ID: NCT00026338

CompletadoFase 3ClinicalTrials.gov

A Phase III Randomised, Double-blind Trial to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10 mg Compared to Placebo, in Patients With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF)

IntervencionalInicio: 6 de mar de 2017ID: NCT03057977

CompletadoClinicalTrials.gov

Survey on Tobacco Use in the GN Sites

ObservacionalInicio: 1 de feb de 2004ID: NCT00121368

CompletadoFase 3ClinicalTrials.gov

A Randomized Double-Blind Phase III Study of Ipilimumab Administered at 3 mg/kg Versus at 10 mg /kg in Subjects With Previously Treated or Untreated Unresectable or Metastatic Melanoma

IntervencionalInicio: 17 de feb de 2012ID: NCT01515189

CompletadoFase 3ClinicalTrials.gov

Estudio de fase 3, multicéntrico, aleatorizado, doble ciego, controlado con placebo, para evaluar la eficacia y seguridad de baricitinib en combinación con corticosteroides tópicos en pacientes adultos con dermatitis atópica moderada a grave. BREEZE-AD7.

IntervencionalInicio: 16 de nov de 2018ID: NCT03733301

ReclutandoFase 3ClinicalTrials.gov

Estudio global de fase III, aleatorizado, doble ciego, multicéntrico de rilvegostomig o pembrolizumab en monoterapia para el tratamiento de primera línea de pacientes con cáncer de pulmón de células no pequeñas metastásico con PD-L1 alto (ARTEMIDE-Lung04)

IntervencionalInicio: 10 de abr de 2025ID: NCT06868277